CN112368381A - 用于治疗高胆固醇血症和相关病况的pcsk9靶向寡核苷酸 - Google Patents

用于治疗高胆固醇血症和相关病况的pcsk9靶向寡核苷酸 Download PDF

Info

Publication number
CN112368381A
CN112368381A CN201980041119.4A CN201980041119A CN112368381A CN 112368381 A CN112368381 A CN 112368381A CN 201980041119 A CN201980041119 A CN 201980041119A CN 112368381 A CN112368381 A CN 112368381A
Authority
CN
China
Prior art keywords
oligonucleotide
nucleotides
length
antisense strand
pcsk9
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
CN201980041119.4A
Other languages
English (en)
Chinese (zh)
Inventor
H·T·杜德克
朴智慧
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dicerna Pharmaceuticals Inc
Original Assignee
Dicerna Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dicerna Pharmaceuticals Inc filed Critical Dicerna Pharmaceuticals Inc
Publication of CN112368381A publication Critical patent/CN112368381A/zh
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21061—Kexin (3.4.21.61), i.e. proprotein convertase subtilisin/kexin type 9
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/533—Physical structure partially self-complementary or closed having a mismatch or nick in at least one of the strands

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
CN201980041119.4A 2018-04-18 2019-04-01 用于治疗高胆固醇血症和相关病况的pcsk9靶向寡核苷酸 Withdrawn CN112368381A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862659693P 2018-04-18 2018-04-18
US62/659693 2018-04-18
US201962820558P 2019-03-19 2019-03-19
US62/820558 2019-03-19
PCT/US2019/025253 WO2019204021A1 (en) 2018-04-18 2019-04-01 Pcsk9 targeting oligonucleotides for treating hypercholesterolemia and related conditions

Publications (1)

Publication Number Publication Date
CN112368381A true CN112368381A (zh) 2021-02-12

Family

ID=68239855

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980041119.4A Withdrawn CN112368381A (zh) 2018-04-18 2019-04-01 用于治疗高胆固醇血症和相关病况的pcsk9靶向寡核苷酸

Country Status (10)

Country Link
US (2) US11566248B2 (https=)
EP (1) EP3765611A4 (https=)
JP (2) JP7357002B2 (https=)
KR (1) KR102749200B1 (https=)
CN (1) CN112368381A (https=)
AU (1) AU2019255460A1 (https=)
CA (1) CA3097585A1 (https=)
IL (1) IL278086A (https=)
MX (1) MX2020011006A (https=)
WO (1) WO2019204021A1 (https=)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115992138A (zh) * 2021-09-30 2023-04-21 北京安龙生物医药有限公司 用于治疗与pcsk9相关疾病的靶向寡核苷酸
WO2023134609A1 (zh) * 2022-01-13 2023-07-20 石药集团中奇制药技术（石家庄）有限公司 一种抑制PCSK9基因表达的RNAi剂及其应用
CN117106781A (zh) * 2023-10-16 2023-11-24 深圳市茵冠生物科技有限公司 修饰的核酸及其产品和应用
CN117210468A (zh) * 2023-11-06 2023-12-12 北京悦康科创医药科技股份有限公司 靶向调控PCSK9基因表达的siRNA及其应用
WO2023241591A1 (zh) * 2022-06-14 2023-12-21 大睿生物医药科技(上海)有限公司 调控PCSK9基因活性的siRNA分子
CN117384907A (zh) * 2023-12-11 2024-01-12 上海鼎新基因科技有限公司 抑制PCSK9表达的siRNA分子及其应用
CN118109463A (zh) * 2024-01-31 2024-05-31 北京悦康科创医药科技股份有限公司 靶向PCSK9基因的siRNA及其应用
WO2025060884A1 (zh) * 2023-09-18 2025-03-27 广州必贝特医药股份有限公司 用于同时抑制两个靶基因表达的siRNA、药物及其应用
WO2026026811A1 (zh) * 2024-07-29 2026-02-05 成都先衍生物技术有限公司 一种具有双靶点基因抑制作用的核酸缀合物及其应用
WO2026026812A1 (zh) * 2024-07-29 2026-02-05 成都先衍生物技术有限公司 一种具有双靶点基因抑制作用的核酸缀合物及其应用

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019006455A1 (en) 2017-06-30 2019-01-03 Solstice Biologics, Ltd. AUXILIARIES OF CHIRAL PHOSPHORAMIDITIS AND METHODS OF USE THEREOF
US11566248B2 (en) 2018-04-18 2023-01-31 Dicerna Pharmaceuticals, Inc. PCSK9 targeting oligonucleotides for treating hypercholesterolemia and related conditions
WO2020226960A1 (en) 2019-05-03 2020-11-12 Dicerna Pharmaceuticals, Inc. Double-stranded nucleic acid inhibitor molecules with shortened sense strands
US20220290156A1 (en) * 2019-08-27 2022-09-15 Sanofi Compositions and methods for inhibiting pcsk9
WO2022089486A1 (zh) * 2020-10-28 2022-05-05 江苏柯菲平医药股份有限公司 抑制PCSK9基因表达的siRNA及其修饰物与应用
CN114634929A (zh) * 2020-12-16 2022-06-17 施能康生物科技有限公司 靶向前蛋白转化酶枯草杆菌转化酶的核酸及其用途
WO2023017004A1 (en) * 2021-08-09 2023-02-16 Cargene Therapeutics Pte. Ltd. Inhibitory nucleic acids for pcsk9
CN118086311B (zh) * 2023-05-25 2024-08-09 苏州时安生物技术有限公司 抑制PCSK9基因表达的siRNA、其缀合物和药物组合物及用途
CN121866332A (zh) * 2023-06-21 2026-04-14 美国圣因生物股份有限公司 靶向前蛋白转化酶枯草杆菌蛋白酶kexin 9（pcsk9）的双链rna及其使用方法
WO2025096355A1 (en) * 2023-10-29 2025-05-08 Corsera Llc Improved sirna for silencing expression of pcsk9 and uses thereof

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008109369A2 (en) * 2007-03-02 2008-09-12 Mdrna, Inc. Nucleic acid compounds for inhibiting tnf gene expression and uses thereof
US20100144834A1 (en) * 2006-11-27 2010-06-10 Isis Pharmaceuticals, Inc. Methods for treating hypercholesterolemia
US20110065644A1 (en) * 2008-03-09 2011-03-17 Intradigm Corporation Compositions comprising human pcsk9 and apolipoprotein b sirna and methods of use
CN102458366A (zh) * 2009-06-15 2012-05-16 阿尔尼拉姆医药品有限公司 靶向pcsk9基因的脂质配制的dsrna
US20170137823A1 (en) * 2009-01-05 2017-05-18 Rxi Pharmaceuticals Corporation Inhibition of pcsk9 through rnai
WO2019204021A1 (en) * 2018-04-18 2019-10-24 Dicerna Pharmaceuticals, Inc. Pcsk9 targeting oligonucleotides for treating hypercholesterolemia and related conditions

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2874149T3 (es) * 2006-05-11 2021-11-04 Alnylam Pharmaceuticals Inc Composiciones y métodos para inhibir la expresión del gen PCSK9
AU2007275365A1 (en) * 2006-07-17 2008-01-24 Sirna Therapeutics Inc. RNA interference mediated inhibition of Proprotein Convertase Subtilisin Kexin 9 (PCSK9) gene expression using short interfering nucleic acid (siNA)
WO2012058693A2 (en) 2010-10-29 2012-05-03 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibition of pcsk9 genes
JP7105065B2 (ja) * 2014-12-15 2022-07-22 ダイセルナ ファーマシューティカルズ， インコーポレイテッド リガンド修飾二本鎖核酸

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100144834A1 (en) * 2006-11-27 2010-06-10 Isis Pharmaceuticals, Inc. Methods for treating hypercholesterolemia
WO2008109369A2 (en) * 2007-03-02 2008-09-12 Mdrna, Inc. Nucleic acid compounds for inhibiting tnf gene expression and uses thereof
US20110065644A1 (en) * 2008-03-09 2011-03-17 Intradigm Corporation Compositions comprising human pcsk9 and apolipoprotein b sirna and methods of use
US20170137823A1 (en) * 2009-01-05 2017-05-18 Rxi Pharmaceuticals Corporation Inhibition of pcsk9 through rnai
CN102458366A (zh) * 2009-06-15 2012-05-16 阿尔尼拉姆医药品有限公司 靶向pcsk9基因的脂质配制的dsrna
WO2019204021A1 (en) * 2018-04-18 2019-10-24 Dicerna Pharmaceuticals, Inc. Pcsk9 targeting oligonucleotides for treating hypercholesterolemia and related conditions

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120272480A (zh) * 2021-09-30 2025-07-08 北京安龙生物医药有限公司 用于治疗与pcsk9相关疾病的靶向寡核苷酸
CN115992138A (zh) * 2021-09-30 2023-04-21 北京安龙生物医药有限公司 用于治疗与pcsk9相关疾病的靶向寡核苷酸
WO2023134609A1 (zh) * 2022-01-13 2023-07-20 石药集团中奇制药技术（石家庄）有限公司 一种抑制PCSK9基因表达的RNAi剂及其应用
WO2023241591A1 (zh) * 2022-06-14 2023-12-21 大睿生物医药科技(上海)有限公司 调控PCSK9基因活性的siRNA分子
WO2025060884A1 (zh) * 2023-09-18 2025-03-27 广州必贝特医药股份有限公司 用于同时抑制两个靶基因表达的siRNA、药物及其应用
CN117106781B (zh) * 2023-10-16 2024-03-22 深圳市茵冠生物科技有限公司 修饰的核酸及其产品和应用
CN117106781A (zh) * 2023-10-16 2023-11-24 深圳市茵冠生物科技有限公司 修饰的核酸及其产品和应用
CN117210468B (zh) * 2023-11-06 2024-02-20 北京悦康科创医药科技股份有限公司 靶向调控PCSK9基因表达的siRNA及其应用
CN117210468A (zh) * 2023-11-06 2023-12-12 北京悦康科创医药科技股份有限公司 靶向调控PCSK9基因表达的siRNA及其应用
CN117384907B (zh) * 2023-12-11 2024-03-29 上海鼎新基因科技有限公司 抑制PCSK9表达的siRNA分子及其应用
CN117384907A (zh) * 2023-12-11 2024-01-12 上海鼎新基因科技有限公司 抑制PCSK9表达的siRNA分子及其应用
CN118109463A (zh) * 2024-01-31 2024-05-31 北京悦康科创医药科技股份有限公司 靶向PCSK9基因的siRNA及其应用
CN118109463B (zh) * 2024-01-31 2025-02-21 北京悦康科创医药科技股份有限公司 靶向PCSK9基因的siRNA及其应用
WO2026026811A1 (zh) * 2024-07-29 2026-02-05 成都先衍生物技术有限公司 一种具有双靶点基因抑制作用的核酸缀合物及其应用
WO2026026812A1 (zh) * 2024-07-29 2026-02-05 成都先衍生物技术有限公司 一种具有双靶点基因抑制作用的核酸缀合物及其应用

Also Published As

Publication number Publication date
CA3097585A1 (en) 2019-10-24
JP2023174697A (ja) 2023-12-08
KR20210005068A (ko) 2021-01-13
IL278086A (en) 2020-11-30
KR102749200B1 (ko) 2025-01-03
JP7357002B2 (ja) 2023-10-05
AU2019255460A1 (en) 2020-11-12
MX2020011006A (es) 2021-01-20
US20210238606A1 (en) 2021-08-05
US11566248B2 (en) 2023-01-31
EP3765611A4 (en) 2022-05-04
EP3765611A1 (en) 2021-01-20
WO2019204021A1 (en) 2019-10-24
US20230250435A1 (en) 2023-08-10
JP2021521796A (ja) 2021-08-30

Similar Documents

Publication Publication Date Title
US20230250435A1 (en) Pcsk9 targeting oligonucleotides for treating hypercholesterolemia and related conditions
JP7749645B2 (ja) Ａｎｇｐｔｌ３発現を阻害する組成物及び方法
US11478501B2 (en) Compositions and methods for inhibiting HMGB1 expression
CN111601891A (zh) 用于抑制aldh2表达的组合物和方法
US12534730B2 (en) Compositions and methods for inhibiting GYS2 expression
US20220072024A1 (en) Compositions and methods for inhibiting hmgb1 expression
CN118355120A (zh) 用于调节apoc3表达的组合物和方法
EP3908661A1 (en) Methods and compositions for inhibiting expression of cyp27a1
KR20250005108A (ko) Scap 활성을 조절하기 위한 조성물 및 방법
HK40028777A (en) Compositions and methods for inhibiting hmgb1 expression

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WW01 Invention patent application withdrawn after publication
WW01 Invention patent application withdrawn after publication

Application publication date: 20210212